Goldman Sachs
GSK icon

Goldman Sachs’s GSK GSK Stock Holding History

Goldman Sachs’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529M Buy
9,589,114
+2,347,296
+32% +$127M 0.06% 324
2025
Q4 		$355M Buy
7,241,818
+722,887
+11% +$33.7M 0.04% 410
2025
Q3 		$281M Buy
6,518,931
+223,939
+4% +$8.75M 0.03% 481
2025
Q2 		$242M Sell
6,294,992
-2,767,895
-31% -$106M 0.03% 504
2025
Q1 		$351M Sell
9,062,887
-620,277
-6% -$22.7M 0.06% 345
2024
Q4 		$327M Buy
9,683,164
+2,312,724
+31% +$83.3M 0.05% 346
2024
Q3 		$301M Buy
7,370,440
+3,214,053
+77% +$131M 0.05% 380
2024
Q2 		$160M Buy
4,156,387
+92,241
+2% +$3.88M 0.03% 580
2024
Q1 		$174M Buy
4,064,146
+49,113
+1% +$2.03M 0.03% 545
2023
Q4 		$149M Sell
4,015,033
-1,213,268
-23% -$43.6M 0.03% 594
2023
Q3 		$190M Sell
5,228,301
-3,577,952
-41% -$127M 0.04% 448
2023
Q2 		$314M Sell
8,806,253
-1,004,595
-10% -$36M 0.07% 274
2023
Q1 		$349M Buy
9,810,848
+99,483
+1% +$3.48M 0.08% 244
2022
Q4 		$341M Buy
9,711,365
+1,649,886
+20% +$55M 0.08% 239
2022
Q3 		$237M Buy
8,061,479
+1,552,403
+24% +$58.8M 0.06% 329
2022
Q2 		$354M Buy
6,509,076
+818,645
+14% +$45.2M 0.09% 191
2022
Q1 		$310M Buy
5,690,431
+1,852,963
+48% +$101M 0.07% 290
2021
Q4 		$212M Buy
3,837,468
+1,092,320
+40% +$56.8M 0.04% 436
2021
Q3 		$131M Buy
2,745,148
+56,643
+2% +$2.85M 0.03% 603
2021
Q2 		$134M Buy
2,688,505
+729,544
+37% +$35.1M 0.03% 573
2021
Q1 		$87.4M Sell
1,958,961
-1,048,598
-35% -$47.6M 0.02% 740
2020
Q4 		$138M Buy
3,007,559
+1,096,276
+57% +$50.4M 0.04% 462
2020
Q3 		$89.9M Sell
1,911,283
-222,662
-10% -$11.2M 0.03% 627
2020
Q2 		$109M Sell
2,133,945
-564,039
-21% -$28.9M 0.03% 518
2020
Q1 		$128M Buy
2,697,984
+125,195
+5% +$6.68M 0.05% 424
2019
Q4 		$151M Buy
2,572,789
+228,748
+10% +$12.7M 0.04% 501
2019
Q3 		$125M Buy
2,344,041
+286,858
+14% +$14.8M 0.04% 536
2019
Q2 		$103M Sell
2,057,183
-85,526
-4% -$4.29M 0.03% 648
2019
Q1 		$112M Buy
2,142,709
+99,843
+5% +$4.99M 0.03% 591
2018
Q4 		$97.6M Sell
2,042,866
-452,695
-18% -$22.3M 0.03% 619
2018
Q3 		$125M Buy
2,495,561
+130,477
+6% +$6.63M 0.03% 624
2018
Q2 		$119M Sell
2,365,084
-84,819
-3% -$4.27M 0.03% 628
2018
Q1 		$120M Buy
2,449,903
+573,945
+31% +$26.7M 0.03% 671
2017
Q4 		$83.2M Sell
1,875,958
-179,840
-9% -$8.31M 0.02% 917
2017
Q3 		$104M Sell
2,055,798
-179,507
-8% -$9.11M 0.03% 784
2017
Q2 		$120M Sell
2,235,305
-369,726
-14% -$19.7M 0.03% 657
2017
Q1 		$137M Sell
2,605,031
-48,559
-2% -$2.46M 0.04% 555
2016
Q4 		$128M Buy
2,653,590
+58,158
+2% +$2.87M 0.04% 622
2016
Q3 		$140M Buy
2,595,432
+44,969
+2% +$2.47M 0.04% 522
2016
Q2 		$138M Sell
2,550,463
-33,920
-1% -$1.79M 0.05% 496
2016
Q1 		$131M Buy
2,584,383
+783,177
+43% +$39M 0.04% 531
2015
Q4 		$90.8M Buy
1,801,206
+13,938
+0.8% +$710K 0.03% 725
2015
Q3 		$85.9M Buy
1,787,268
+163,290
+10% +$8.5M 0.03% 704
2015
Q2 		$84.5M Sell
1,623,978
-94,578
-6% -$5.33M 0.03% 768
2015
Q1 		$99.1M Buy
1,718,556
+145,409
+9% +$8.34M 0.03% 645
2014
Q4 		$84M Sell
1,573,147
-355,940
-18% -$19.9M 0.03% 756
2014
Q3 		$111M Buy
1,929,087
+142,178
+8% +$8.72M 0.04% 591
2014
Q2 		$119M Sell
1,786,909
-117,673
-6% -$7.96M 0.04% 580
2014
Q1 		$127M Buy
1,904,582
+369,812
+24% +$25M 0.04% 505
2013
Q4 		$102M Buy
1,534,770
+19,467
+1% +$1.26M 0.03% 627
2013
Q3 		$95M Buy
1,515,303
+120,418
+9% +$7.75M 0.04% 620
2013
Q2 		$87.1M Buy
+1,394,885
New +$88.5M 0.03% 606

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs's GSK Position: Q1 2026 in Review

Goldman Sachs increased its GSK (GSK) stake by 32% in Q1 2026, buying an estimated $127M and bringing the position to 9,589,114 shares worth $529M. The position accounts for 0.06% of the portfolio, ranked #324.

Goldman Sachs first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Goldman Sachs held 9,589,114 shares of GSK worth $529M as of Q1 2026.
  • Goldman Sachs bought 2,347,296 GSK shares in Q1 2026, an estimated $127M.
  • GSK made up 0.06% of Goldman Sachs's portfolio in Q1 2026, its #324 holding.
  • Goldman Sachs first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.